25 years EMA

Fostering scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union

2020 Relocation to the Netherlands completed

2019 EMA elected as ICMRA chair; First vaccine against Ebola

2018 First two CAR-T medicines; New Veterinary Medicines Regulation

2017 First public hearing; Mutual recognition agreement on inspections; Amsterdam is announced as EMA's new home

2016 Proactive publication of clinical data; Launch of PRIME (PRIority Medicines) scheme

2015 First joint strategy of EMA and national medicines authorities

2014 First stem-cell medicine

2012 First gene-therapy medicine

2011 First paediatric-use marketing authorisation; Falsified Medicines Directive; First ESVAC report

2010 New pharmacovigilance legislation

2009 Minor-use-minor-species limited-market policy; First marketing authorisation for an ATMP

2007 First centrally authorised generic medicine

2006 First two biosimilar medicines; Paediatric Medicines Regulation; First conditional approval

2005 SME regulation; SME office established; Herbal Medicines Directive

2004 Review of EU pharmaceutical legislation

2001 Clinical Trials Directive; First two orphan medicines

2000 Orphan Medicines Regulation

1996 First centrally authorised veterinary medicine; Launch of international harmonisation programme for pharmaceuticals

1995 EMA established; First centrally authorised human medicine